Whole-Body Insulin Sensitivity Index Is a Highly Specific Predictive Marker for Virological Response to Peginterferon Plus Ribavirin Therapy in Chronic Hepatitis C Patients with Genotype 1b and High Viral Load

  • Toshihiko Mizuta
  • Yasunori Kawaguchi
  • Yuichiro Eguchi
  • Hirokazu Takahashi
  • Keisuke Ario
  • Takumi Akiyama
  • Noriko Oza
  • Taiga Otsuka
  • Takuya Kuwashiro
  • Toru Yoshimura
  • Akitaka Hisatomi
  • Iwata Ozaki
Original Article

Abstract

Insulin resistance is a candidate predictive factor for virological response to peginterferon plus ribavirin (PEG/RBV) therapy in chronic hepatitis C patients. We examined whether indices of insulin resistance could serve as a predictor of sustained virological response (SVR). Fifty-one patients with genotype 1b and high viral load who received PEG/RBV therapy for 48 weeks were included. Homeostasis model assessment of insulin resistance (HOMA-IR) and whole-body insulin sensitivity index (WBISI) calculated from the 75-g oral glucose tolerance test and serum levels of soluble tumor necrosis factor receptor 2 (sTFNR2) were evaluated before therapy. Patients who achieved SVR had significantly lower HOMA-IR and sTNFR2 levels and a higher WBISI compared with non-SVR patients. The positive predictive value for SVR was 0.653 for a HOMA-IR of <2 and 0.846 for a WBISI of 6 or higher. WBISI may serve as a highly specific predictor for SVR in PEG/RBV therapy.

Keywords

Chronic hepatitis C Peginterferon plus ribavirin therapy Whole-body insulin sensitivity index HOMA-IR Soluble tumor necrosis factor receptor 2 

References

  1. 1.
    Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C: a randomized trial. Lancet. 2001;358:958–965. doi:10.1016/S0140-6736(01)06102-5.CrossRefPubMedGoogle Scholar
  2. 2.
    Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa 2a and ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982. doi:10.1056/NEJMoa020047.CrossRefPubMedGoogle Scholar
  3. 3.
    Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147–1171. doi:10.1002/hep.20119.CrossRefPubMedGoogle Scholar
  4. 4.
    Charlton MR, Pockros P, Harrison SA. Impact of obesity on treatment of chronic hepatitis C. Hepatology. 2006;43:1177–1186. doi:10.1002/hep.21239.CrossRefPubMedGoogle Scholar
  5. 5.
    Harrison SA. Insulin resistance among patients with chronic hepatitis C: etiology and impact on treatment. Clin Gastroenterol Hepatol. 2008;6:864–876. doi:10.1016/j.cgh.2008.03.024.CrossRefPubMedGoogle Scholar
  6. 6.
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia. 1985;28:412–419. doi:10.1007/BF00280883.CrossRefPubMedGoogle Scholar
  7. 7.
    Matsuda M, DeFronzo R. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22:1462–1470. doi:10.2337/diacare.22.9.1462.CrossRefPubMedGoogle Scholar
  8. 8.
    Ohno O, Mizokami M, Wu RR, et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol. 1997;35:201–207.PubMedGoogle Scholar
  9. 9.
    Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539–553. doi:10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S.CrossRefPubMedGoogle Scholar
  10. 10.
    Seltzer HS, Allen EW, Herron AL Jr, Brennan MT. Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. J Clin Invest. 1967;46:323–335. doi:10.1172/JCI105534.CrossRefPubMedGoogle Scholar
  11. 11.
    The French METAVIR Cooperative Study Group, Bedossa P. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology. 1994;20:15–20.Google Scholar
  12. 12.
    Romero-Gómez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis patients. Gastroenterology. 2005;128:636–641. doi:10.1053/j.gastro.2004.12.049.CrossRefPubMedGoogle Scholar
  13. 13.
    D’Souza R, Sabin A, Foster GR. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol.. 2005;100:1509–1515. doi:10.1111/j.1572-0241.2005.41403.x.CrossRefPubMedGoogle Scholar
  14. 14.
    Conjeevaram HS, Kleiner DE, Everhart JE, et al. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology. 2007;45:80–87. doi:10.1002/hep.21455.CrossRefPubMedGoogle Scholar
  15. 15.
    Abdul-Ghani MA, Matsuda M, Balas B, DeFronzo RA. Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test. Diabetes Care. 2007;30:89–94. doi:10.2337/dc06-1519.CrossRefPubMedGoogle Scholar
  16. 16.
    Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology. 2004;126:840–848. doi:10.1053/j.gastro.2003.11.056.CrossRefPubMedGoogle Scholar
  17. 17.
    Pazienza V, Clément S, Pugnale P, et al. The Hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology. 2007;45:1164–1171. doi:10.1002/hep.21634.CrossRefPubMedGoogle Scholar
  18. 18.
    Taura N, Ichikawa T, Hamasaki K, et al. Association between liver fibrosis and insulin sensitivity in chronic hepatitis C patients. Am J Gastroenterol. 2006;101:2752–2759.CrossRefPubMedGoogle Scholar
  19. 19.
    Lecube A, Hernández C, Genescà J, Simó R. Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: a case-control study. Diabetes Care. 2006;29:1096–1101. doi:10.2337/dc05-2509.CrossRefPubMedGoogle Scholar
  20. 20.
    Lang CH, Dobrescu C, Bagby GJ. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose uptake. Endocrinology. 1992;130:43–52. doi:10.1210/en.130.1.43.CrossRefPubMedGoogle Scholar
  21. 21.
    Eguchi Y, Mizuta T, Yasutake T, et al. High serum leptin is an independent risk factor for non-response in patients with low viremia to antiviral treatment in chronic hepatitis C. World J Gastroenterol. 2006;12:556–560.PubMedGoogle Scholar
  22. 22.
    Grunfeld C, Zhao C, Fuller J, et al. Endotoxin and cytokine induce expression of leptin, the OB gene product, in hamster. J Clin Invest. 1996;97:2152–2157. doi:10.1172/JCI118653.CrossRefPubMedGoogle Scholar
  23. 23.
    Fernández-Real JM, Broch M, Ricart W, et al. Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance. Diabetes. 1998;47:1757–1762. doi:10.2337/diabetes.47.11.1757.CrossRefPubMedGoogle Scholar
  24. 24.
    Vlotides G, Sörensen AS, Kopp F, et al. SOCS-1 and SOCS-3 inhibit IFN-a-induced expression of the antiviral proteins 2,5-OAS and MxA. Biochem Biophys Res Commun. 2004;320:1007–1014. doi:10.1016/j.bbrc.2004.06.051.CrossRefPubMedGoogle Scholar
  25. 25.
    Kawaguchi T, Yoshida T, Harada M, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol. 2004;165:1499–1508.PubMedGoogle Scholar
  26. 26.
    Persico M, Capasso M, Persico E, et al. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus–related chronic hepatitis: insulin resistance and response to antiviral therapy. Hepatology. 2007;46:1009–1015. doi:10.1002/hep.21782.CrossRefPubMedGoogle Scholar
  27. 27.
    Sass G, Shembade ND, Tiegs G. Tumour necrosis factor α (TNF)–TNF receptor 1-inducible cytoprotective proteins in the mouse liver: relevance of suppressors of cytokine signaling. Biochem J. 2005;385:537–544. doi:10.1042/BJ20040279.CrossRefPubMedGoogle Scholar
  28. 28.
    Knobler H, Schattner A. TNF-α, chronic hepatitis C and diabetes: a novel triad. QJM. 2005;98:1–6. doi:10.1093/qjmed/hci001.CrossRefPubMedGoogle Scholar
  29. 29.
    Overbeck K, Genné D, Golay A, Negro F. Pioglitazone in chronic hepatitis C not responding to pegylated interferon-α and ribavirin. J Hepatol. 2008;49:295–298. doi:10.1016/j.jhep.2008.03.033.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Toshihiko Mizuta
    • 1
  • Yasunori Kawaguchi
    • 1
  • Yuichiro Eguchi
    • 1
  • Hirokazu Takahashi
    • 1
  • Keisuke Ario
    • 1
  • Takumi Akiyama
    • 1
  • Noriko Oza
    • 1
  • Taiga Otsuka
    • 1
  • Takuya Kuwashiro
    • 1
  • Toru Yoshimura
    • 1
  • Akitaka Hisatomi
    • 1
  • Iwata Ozaki
    • 1
  1. 1.Department of Internal MedicineSaga Medical SchoolSagaJapan

Personalised recommendations